- Invitae ( NYSE: NVTA ) expects prelim Q4 revenue of ~$122M vs. analysts estimates of $121.41M.
- Revenue is expected to fall from $126M a year ago due to the exited businesses and geographies. The medical genetics company generated revenue of approximately $516M (consensus: $515.60M) in 2022, or about a 12% increase from $460M in 2021.
- Total active healthcare provider accounts grew 8% from 2021 to ~20,000, while active pharma and commercial partnerships grew to ~230 (+29%).
- As of December 31, 2022, cash, cash equivalents, restricted cash and marketable securities were greater than $555M.
- Invitae ( NVTA ) will report its full financial results and other metrics during its fourth quarter and year-end 2022 conference call in late February.
- NVTA shares were up around 2% shortly before 11AM ET.
For further details see:
Invitae guides Q4 revenue above estimates